This editorial refers to 'Atrial fibrillation as a risk factor for cognitive decline and dementia' † , by A. Singh-Manoux et al.,
Both atrial fibrillation (AF) and dementia are diseases of elderly people. The incidence of AF and cognitive decline increases with age. The coincidence of the two frequent conditions might be simply explained by a common factor, namely increasing age. Recent research, however, provided evidence that vascular risk factors and vascular disease contribute not only to vascular dementia but also to degenerative dementias such as Alzheimer's disease. 1 AF increases the risk of stroke by a factor of five, and stroke is an important risk factor and predictor of cognitive decline and dementia. A number of studies indicated that AF might increase the risk of faster cognitive decline and dementia even in patients without prior stroke. Most of these studies were retrospective in nature. Therefore, results from prospective long-term studies are needed. Singh-Manoux et al., in their study published in this issue of the journal, used prospectively collected data from the Whitehall II study. A total of 10 308 persons aged 33-45 years were recruited into the study between 1985 and 1988 and followed until 2013. The relationship between AF, cognitive impairment, and dementia was also shown in two recent meta-analyses. Kalantarian et al. 4 identified 21 studies with 89 907 participants and investigated the association of AF with cognitive decline and dementia. AF was significantly associated with a higher risk of cognitive impairment independent of a history of stroke [relative risk (RR) 1.34, 95% CI 1.13-1.58]. The risk of dementia was also significantly increased (RR 1.38, 95% CI 1.22-1.56). A second meta-analysis included 46 637 participants from 15 studies and showed that AF was associated with a significant increase in dementia (odds ratio 2.0, 95% CI 1.4-2.7) with a strong contribution of patients with previous stroke.
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What are the possible mechanisms leading to cognitive decline and dementia in patients with AF? (Figure 1) . (i) AF results in decreased cardiac output and may result in chronic cerebral hypoperfusion. 6 Cerebral hypoperfusion may lead to leucoaraiosis and cognitive decline and also promote Alzheimer's disease. 7 (ii) AF increases the risk of stroke and therefore increases the risk of cognitive decline and dementia. (iii) AF may result in silent strokes. Silent strokes are associated with cognitive decline and dementia. 8 (iv) AF may result in microemboli leading to asymptomatic small lacunar defects or cerebral microbleeds. How might treatment of AF decrease the risk of cognitive decline and dementia? Cardioversion or AF ablation might result in sinus rhythm and improve cardiac output and cerebral perfusion. Optimal anticoagulation reduces the risk of ischaemic stroke, silent infarcts, and possibly the occurrence of microemboli. The randomized studies investigating non vitamin-K oral anticoagulants (NOACs) vs. warfarin showed in aggregate a reduction in the risk of stroke. 9 They would have been too short to show an impact on cognition. Prospective trials investigating the potential benefit of rhythm control or anticoagulation in AF would need to run for 10 years to show an impact on cognitive decline and dementia, and would require many thousands of patients. Therefore it is unlikely that these trials will ever be funded. We are restricted at the moment with analyses from large databases in Denmark, Sweden, or the UK which are underway. In conclusion, AF is associated with cognitive decline and dementia. It is very likely that treatment of AF and anticoagulation may prevent or delay cognitive decline and dementia. 
